Novel Discoveries Start Here.
There are billions of theoretical combinations of small molecules in nature. Less than one-tenth of one percent of these compounds have been explored as pharmaceutical products, yet over 40 percent of the drugs on the market today originated from natural sources. Natural products make good drugs because they have existed in a biological system and offer unmatched diversity, providing many unique and patentable chemical structures – and that’s where Magellan comes in.

Magellan partners with research companies and academic centers to tap into the diversity and novelty of our natural product compounds and maximize the prospects for new discoveries and breakthroughs. We can create fully customized programs with our partners to address your specific needs.

alliances and collaborations

		AndroBioSys - AndroBioSys focuses its efforts on identifying specific targets in prostate tumors (e.g. prostate vasculature, tumor stem cells and androgen metabolism) which may be developed to improve prostate cancer treatment. Using unique human cell and tissue-based screening tools, the company will identify candidate drug compounds with angiogenic activity or compounds that inhibit androgen biosynthesis.
		BioFlorida - As the statewide trade association for the bioscience industry, BioFlorida provides companies with the necessary resources to succeed, and a strong marketing presence both locally and internationally.
		Evolva, SA - Evolva and Magellan are teaming up to create "chemistry enabled" recombinant micro-organisms that express diverse chemistry encoding genes from other species, enabling them to synthesize heterologous compounds. Magellan’s library of micro-organisms will be screened against pharmaceutical targets, looking for those individual micro-organisms that make compounds that best hit the assay.
		Hawaii Pacific University - Several members of the transient receptor potential cation channels family have been implicated in playing a role in the damage to nerve and heart tissue following stroke and heart attack. Magellan and HPU are partnering to investigate the inhibitory effects of microbial metabolites on these and other channels using cells engineered to over-express channel proteins while monitoring the influx of calcium and other ions into cells. Microbial compounds that are found to directly modulate the function of our target ion channels will be characterized and further investigated for their pharmacological potential.
		Kemin Pharmaceuticals - Magellan Bioscience Group, Inc. is providing to Kemin its compounds and extracts from fermentation broths of marine-isolated microorganisms to be screened in a variety of anti-infective assays including anti-bacterial, anti-fungal and anti-viral.
		Memorial Sloan-Kettering Cancer Center - This collaboration brings together Magellan’s collection of marine-derived natural products as well as their natural product chemistry expertise with MSKCC’s high-throughput screening technologies and clinical research expertise. MSKCC will undertake the characterization of lead candidates from Magellan’s collection using MSKCC’s proprietary assays and will jointly optimize obtained leads towards drug candidates. In addition to its libraries, Magellan will also provide access to its various chemistry technologies, to stimulate and accelerate early discovery efforts.
		Mycologics, Inc. - Magellan’s library is being screened using Mycologics’ proprietary assays to search for compounds that specifically inhibit an essential Leishmania major enzyme. If successful, this could lead to an exciting new class of safe and effective anti-Leishmania therapeutics.
		Thrombotargets - Magellan Bioscience Group, Inc. will provide to Thrombotargets its compounds and extracts from fermentation broths of marine-isolated microorganisms to be screened through the revolutionary High Throughput Screening of Pathway Activity, BIOPLATFORMSCREEN™ technology. This modified HTS platforms allows to both Thrombotargets and partners to identify novel hits for entire Pathways regulating a certain biological activity.
		University of Medicine & Dentistry of New Jersey - Together with Dr. Scott Kachlany we are using a novel bioluminescent HL-60 screen for anti-leukemia therapeutics; we hope to identify marine-derived lead compounds that show activity under physiological conditions. Our screen is carried out in the presence of whole blood to more closely model the biology of the human body.
		USF – Together with Drs. Dennis Kyle and Alberto van Olphen of the Center for Biological Defense, Department of Global Health and Dr. Bill Baker in the Department of Chemistry we are examining marine organisms against a variety of targets including influenza, Leishmania and malaria.

For more information, call 813-623-6800 or contact us by email.